Immunohistochemical study of microvessel density, CD44 (standard form), p53 protein and c-erbB2 in gallbladder carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 19, Issue 7, 2004, Pages 812-818

  Kalekou, Harikleia ^a   Miliaras, Dimosthenis ^a,b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Lab of Histology and Embryology Medical Faculty Aristotle University of Thessaloniki ^*  (Greece)

Author keywords

Angiogenesis; c erbB2; CD44; Gallbladder carcinoma; p53

Indexed keywords

CELL ADHESION MOLECULE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HERMES ANTIGEN; PARAFFIN; PROTEIN P53; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CANCER INVASION; CAPILLARY DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GALLBLADDER CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MALE; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; TISSUE DIFFERENTIATION;

EID: 3242753527     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2004.03357.x     Document Type: Article

References (45)

1. Levin B. Gallbladder carcinoma. Ann. Oncol. 1999; 4 (Suppl.): 129-30.
2. Batsakis JG, El-Naggar AK. p53: fifteen years after discovery. Adv. Anat. Pathol. 1995; 2: 71-88.
3. Watanabe H, Date K, Itoi T et al. Histological and genetic changes in malignant transformation of gallbladder adenoma. Ann. Oncol. 1999; 4 (Suppl.): 136-9.
4. Hanada K, Itoh M, Fujii K, Tsuchida A, Ooishi H, Kajiyama G. K-ras and p53 mutations in stage I gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Cancer 1996; 77: 452-8.
5. Sahin AA. Biologic and clinical significance of HER-2/neu (cerbB2) in breast cancer. Adv. Anat. Pathol. 2000; 7: 158-66.
6. de Bono JS, Rowinsky EK. The ErbB receptor family: a therapeutic target for cancer. Trends Mol. Med. 2002; 8 (Suppl.): S19-26.
7. Kamel D, Paakko P, Nuorva K, Vahakangas K, Soini Y. p53 and c-erbB2 protein expression in adenocarcinomas and epithelial dysplasias of the gallbladder. J. Pathol. 1993; 170: 67-72.
8. Weidner N, Semple PJ, Welch WR, Folkman J. Tumor angiogenesis and metastasis correlation in invasive breast carcinoma. N. Engl. J. Med. 1991; 324: 1-8.
9. Takebayashi Y, Akiyama S, Yamada K, Akiba S, Aikou T. Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer 1996; 78: 226-31.
10. Vermeulen PB, Van den Eynden GG, Huget P et al. Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer. Br. J. Cancer 1999; 79: 316-22.
11. Fontanini G, Vignati S, Pacini F, Pollina L, Basolo F. Microvessel count: an indicator of poor outcome in medullary thyroid carcinoma. Mod. Pathol. 1996; 9: 636-41.
12. Kieser A, Weich HA, Brandner G, Marme D, Kolch W. Mutant p53 potentiates protein kinase C induction of VEGF. Oncogene 1994; 9: 963-9.
13. Kang SM, Maeda K, Onoda N et al. Combined analysis of p53 and VEGF expression in colorectal carcinoma for determination of tumor vasculariry and liver metastasis. Int. J. Cancer 1997; 74: 502-7.
14. Kumar R, Yarmand-Bagheri R. The role of HER2 in angiogenesis. Semin. Oncol. 2001; 28 (Suppl. 16): 27-32.
15. Griffioen AW, Coenen MJ, Damen CA et al. CD44 is involved in tumor angiogenesis; an activation antigen on human endothelial cells. Blood 1997; 90: 1150-9.
16. Yamamoto S, Fujii K, Kitadai Y, Yamamoto S, Tsuchida A, Kajiyama G. Expression of vascular endothelial growth factor in human gallbladder lesions. Oncol. Rep. 1998; 5: 1065-9.
17. Sugawara Y, Makuuchi M, Harihara Y et al. Tumor angiogenesis in gallbladder carcinoma. Hepatogastroenterology 1999; 46: 1682-6.
18. Okita S, Kondoh S, Shiraishi K, Kaino S, Hatano S, Okita K. Expression of VEGF correlates with tumor progression in gallbladder cancer. Int. J. Oncol. 1998; 12: 1013-18.
19. Yamamoto S, Kitadai Y, Tsuchida A, Sasaki T, Matsubara K, Kajiyama G. Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human gallbladder lesions. Eur. J. Cancer 2000; 36: 257-63.
20. Giatromanolaki A, Sivridis E, Koukourakis MI, Polychronidis A, Simopoulos C. Prognostic role of angiogenesis in operable carcinoma of the gallbladder. Am. J. Clin. Oncol. 2002; 25: 38-41.
21. Giatromanolaki A, Sivridis E, Simopoulos C et al. Thymidine phosphorylase expression in gallbladder adenocarcinomas. Int. J. Surg. Pathol. 2002; 10: 181-8.
22. Cobbold S, Hale G, Waldmann H. In: McMichael AJ, ed. Leukocyte Typing III. White Cell Differentiation Antigens. Oxford: Oxford University Press, 1987; 788-803.
23. Günthert U, Hofmann M, Rudy W et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65: 13-24.
24. Woodman AC, Sugiyama M, Yoshida K et al. Analysis of anomalous CD44 gene expression in human breast, bladder, and colon cancer and correlation of observed mRNA and protein isoforms. Am. J. Pathol. 1991; 149: 1519-30.
25. Mulder J-WR, Kruyt PM, Sewnath M et al. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 1994; 344: 1470-2.
26. Finke LH, Terpe HJ, Zorb C, Haensch W, Schlag PM. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 1995; 345: 583.
27. Kaufmann M, Heider K-H, Sinn H-P, von Minckwitz G, Ponta H, Herrlich P. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 1991; 345: 615-19.
28. Foekens JA, Dall P, Klijn JG et al. Prognostic value of CD44 variant expression in primary breast cancer. Int. J. Cancer 1999; 84: 209-15.
29. Roa I, Villaseca M, Araya J et al. CD44 (HCAM) expression in subserous gallbladder carcinoma. Rev. Med. Chil. 2001; 129: 727-34.
30. Yanagisawa N, Mikami T, Mitomi H, Saegusa M, Koike M, Okayasu I. CD44 variant overexpression in gallbladder carcinoma associated with tumor dedifferentiation. Cancer 2001; 91: 408-16.
31. Vermeulen PB, Gasparini G, Fox SB et al. Quantification of angiogenesis in solid human tumors: an international consensus on the methodology and criteria evaluation. Eur. J. Cancer 1996; 32: 2474-84.
32. Folkman J. The role of angiogenesis in tumor growth. Semin. Cancer Biol. 1992; 3: 65-71.
33. Koura AN, van Golen K, Tsan R, Radinsky R, Price JE, Ellis LM. Regulation of genes associated with angiogenesis, growth and metastasis by specific point mutations in a murine melanoma cell line. Oncol. Rep. 1997; 4: 475-9.
34. Roa I, Villaseca M, Araya J et al. p53 tumour suppressor gene protein expression in early and advanced gallbladder carcinoma. Histopathology 1997; 31: 226-30.
35. Washington K, Gottfried MR. Expression of p53 in adenocarcinoma of the gallbladder and bile ducts. Liver 1996; 16: 99-104.
36. Wistuba I, Gazdar AF, Roa I, Albores-Saavedra J. p53 protein overexpression in gallbladder carcinoma and its precursor lesions: an immunohistochemical study. Hum. Pathol. 1996; 27: 360-5.
37. Wee A, Tech M, Raju GC. Clinical importance of p53 protein in gallbladder carcinoma and its precursor lesions. J. Clin. Pathol. 1994; 47: 453-6.
38. Herrlich P, Morrison H, Sleeman J et al. CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann. N. Y. Acad. Sci. 2000; 910: 106-20.
39. Bennett KL, Jackson DG, Simon JC et al. CD44 isoforms containing exon v3 are responsible for the presentation of heparin-binding growth factor. J. Cell Biol. 1995; 128: 687-98.
40. Sleeman J, Rudy W, Hofmann M, Moll J, Herrlich P, Ponta H. Regulated clustering of variant CD44 proteins increases their hyaluronate binding capacity. J. Cell Biol. 1996; 135: 1139-50.
41. Foster CS, Gosden CM. HER/neu expression in cancer: the pathologist as diagnostician or prophet? Hum. Pathol. 2003; 34: 635-8.
42. Suzuki T, Takano Y, Kakita A, Okudaira M. An immunohistochemical and molecular biological study of c-erbB2 amplification and prognostic relevance in gall-bladder cancer. Pathol. Res. Pract. 1993; 189: 283-92.
43. Osako T, Miyahara M, Uchino S, Inomata M, Kitano S, Kobayashi M. Immunohistochemical study of c-erbB2 protein in colorectal cancer and the correlation with patient survival. Oncology 1998; 55: 548-55.
44. Kay EW, Mulcahy H, Walsh CB, Leader M, O'Donoghue D. Cytoplasmic c-erbB2 protein expression correlates with survival in Dukes' B colorectal carcinoma. Histopathology 1994; 25: 455-61.
45. Chow NH, Huang SM, Chan SH, Mo LR, Hwang MH, Su WC. Significance of c-erbB2 expression in normal and neoplastic epithelium of biliary tract. Anticancer Res. 1995; 15: 1055-9.